Drug Discovery Outsourcing Market By Workflow (Target Identification and Screening, Target Validation and Functional Informatics, Lead Identification and Candidate Optimization, Preclinical Development, Others), By Therapeutic area (Respiratory system, Infectious disease, Oncology, Immunology, Hematology, Cardiovascular, Central Nervous System (CNS), Gastrointestinal, Others), By Drug Type (Small Molecules, Large Molecules), By End User (Pharmaceutical and Biotechnology companies, Academic Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Drug Discovery Outsourcing Market

Drug discovery outsourcing is used by different companies to reduce costs by transferring portions of work to outside suppliers. Outsourced activities can be carried out in various fields, right from drug discovery to the manufacturing of products.

The Drug Discovery Outsourcing Market Trends is an increase in the incidence of rare genetic disorders and cancer, as well as the rising demand for novel drug delivery technologies. Moreover, the rising usage of AI in drug discovery, as well as the rapid shift toward patent expiration, biologics, and unprecedented downsizing of internal discovery of big pharmaceuticals, and the rising incidences of antibiotic resistance as well as drug resistance, boost the growth of the market.

However, the high cost as well as the high risk of drug failure are the major barriers to the growth of the market. Conversely, emerging economies such as India, China, Mexico, and Brazil are anticipated to create new opportunities during the forecast period.

On the basis of workflow, the target identification and screening segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rapid drug development process and rise in awareness regarding target selection by using various methods such as assay & readers, automation, and high content screening.

On the basis of therapeutic area, the oncology segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rise in the prevalence of cancer cases around the globe, which leads to an increase in the demand to conduct R&D activities for the development of targeted drug therapy against the cancerous cell.

On the basis of drug type, the small molecules segment accounted for the largest share of the market. The dominance of this segment can be attributed to the rapid advancement of biopharmaceutical research and technology for the discovery and some distinct advantages, such as it can be administered orally and can pass through cell membranes to reach intracellular targets more precisely as compared to large molecules.

By end user, the pharmaceutical and biotechnology companies segment exhibited the highest growth in 2021 and is anticipated to lead during the forecast period, owing to rising R&D expenditure of pharmaceutical and biopharmaceutical companies, which is prompting them to opt for fully integrated or functional outsourcing services, from the early development stage to the late-stage development phase, for drug discovery and development.

North America accounted for a majority of the drug discovery outsourcing market share in 2021 and is anticipated to remain dominant during the forecast period owing to the high adoption rate of technologically advanced AI-based drug discovery systems, increase in healthcare expenditure, and the presence of major key players in the country providing outsourcing facilities for the development of novel drug therapies to treat cancer and chronic diseases.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. The market growth in the Asia-Pacific is supplemented by highly populated countries along with a high prevalence rate of genetic disorders and cancer. In addition, the favorable regulatory environment and availability of low-cost skilled manpower with high-quality data in these nations, especially in countries such as India and China, are expected to further drive the Drug Discovery Outsourcing Market Growth.

The key players that operate in the Drug Discovery Outsourcing Industry are Curia Global Inc, Charles River Laboratories Inc, Dr. Reddy’s Laboratories, Discover X Corporation, Dalton Pharma Service, Laboratory Corporation of America Holdings, Merck & Co, Syngene International Ltd, TCG Life Science Pvt. Ltd, and Thermo Fisher Scientific.

Key findings of the study

By workflow, the target identification and screening segment was the highest contributor to the market in 2021.

By therapeutic area, the oncology segment was the highest contributor to the market in 2021.

By type, the small molecules segment was the highest contributor to the market in 2021.

By end user, the pharmaceutical and biotechnology companies dominated the market in 2021 and are expected to continue this trend during the forecast period.

By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global Drug Discovery Outsourcing Market Size was valued at $3.6 billion in 2021 and is projected to reach $7.4 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.. Drug discovery outsourcing is defined as a practice that is used by different companies to reduce the cost of drug development by transferring portions of work to outside suppliers. Outsourced activities can be carried out in various fields, right from drug discovery to the manufacturing of products. Outsourcing drug commercialization to a third-party service provider specializing in drug commercialization helps to ensure the maximization of a drug product’s value proposition.  It is a procedure that is used to find new medicines or drugs in different fields such as pharmacology, pharmaceuticals, and biotechnology.

Moreover, drug discovery contract research organizations (CROs) are engaged in offering a range of research services on a contract basis to pharmaceutical and biotechnology companies for drug discovery. Pharmaceutical companies are now outsourcing their R&D activities to private contract research organizations (CROs) and academic research institutions to reduce drug development time and cost.

The key factors that drive the growth of the market are the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes, and high blood pressure; the increase in R&D activities for drug discovery, and the surge in demand for target drug therapy are the major factors that drive the growth of the drug discovery outsourcing market. For instance, according to the report published by IQVIA in June 2022, the number of trials in oncology drug development reached a historic high of 56% in 2016.  A record 30 oncology novel active substances were initially launched globally in 2021, and a total of 159 have been launched since 2012. Thus, the rise in the number of research activities increases the demand for performing clinical trials to launch new molecules in the market, which increases the demand for outsourcing service providers and hence boosts the growth of the market.

Furthermore, rise in the adoption of outsourcing services by pharmaceutical companies and the increase in the number of key players as CROs for the launch of novel drug therapies are anticipated to fuel the growth of the market. For instance, there are more than 1,000 CROs in the U.S. and Europe. The top 10 accounts for approximately 40% of industry sales. However, CROs have been focused on drug development and clinical trial support, where they can effectively speed the launch of a new drug in the market.

However, the high cost as well as the high risk of drug failure, along with the lack of skilled professionals, hamper the market's growth. Conversely, rising cases of cancer, genetic disease, & chronic disease; large geriatric population; a favorable regulatory environment; and the availability of low-cost skilled manpower with high-quality data in the developing countries are expected to provide a lucrative opportunity for the growth of the market during the forecast period. 

The drug discovery outsourcing market is segmented on the basis of workflow, therapeutic area, drug type, end user, and region. By workflow, it is fragmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, it is classified into the respiratory system, infectious disease, oncology, immunology, hematology, cardiovascular, central nervous system, gastrointestinal, and others. By drug type, it is bifurcated into small molecules and large molecules. By end user, the market is categorized into pharmaceutical & biotechnology companies, academic institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the drug discovery outsourcing market share in 2021 and is anticipated to remain dominant during the forecast period. The drug discovery outsourcing market is mainly driven by the presence of well-established research facilities and a high prevalence rate of cancer & chronic diseases. Moreover, the availability of technologically advanced medical devices and the rise in the demand for target drug therapy techniques to cure cancer are contributing to the growth of the market in this region. Furthermore, an increasing number of key players involved in R&D activities for the discovery of novel drugs is expected to fuel market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is due to the availability of low-cost skilled manpower and high-quality clinical trial data and constantly improving healthcare infrastructure. In addition, the rapidly growing population, rising incidence of cancer & chronic disease, and improvement in the quality of healthcare facilities are set to drive the market in Asia-Pacific. This helps several key market players to invest in Asia-Pacific countries, which in turn, is further expected to contribute to the growth of the market.

The key players that operate in the drug discovery outsourcing market are Curia Global Inc, Charles River Laboratories Inc, Dr. Reddy’s Laboratories, Discover X Corporation, Dalton Pharma Service, Laboratory Corporation of America Holdings, Merck & Co, Syngene International Ltd, TCG Life Science Pvt. Ltd, and Thermo Fisher Scientific.

Key Benefits For Stakeholders 

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the drug discovery outsourcing market analysis from 2021 to 2031 to identify the prevailing drug discovery outsourcing market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the drug discovery outsourcing market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes an analysis of the regional as well as global drug discovery outsourcing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ TCG Life Science Pvt. Lt

Scope of Drug Discovery Outsourcing Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Target Identification and Screening

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Target Validation and Functional Informatics

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

4.4 Lead Identification and Candidate Optimization

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market share analysis by country

4.5 Preclinical Development

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market share analysis by country

4.6 Others

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Respiratory system

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Infectious disease

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

5.4 Oncology

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market share analysis by country

5.5 Immunology

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market share analysis by country

5.6 Hematology

5.6.1 Key market trends, growth factors and opportunities

5.6.2 Market size and forecast, by region

5.6.3 Market share analysis by country

5.7 Cardiovascular

5.7.1 Key market trends, growth factors and opportunities

5.7.2 Market size and forecast, by region

5.7.3 Market share analysis by country

5.8 Central Nervous System (CNS)

5.8.1 Key market trends, growth factors and opportunities

5.8.2 Market size and forecast, by region

5.8.3 Market share analysis by country

5.9 Gastrointestinal

5.9.1 Key market trends, growth factors and opportunities

5.9.2 Market size and forecast, by region

5.9.3 Market share analysis by country

6.0 Others

6.0.1 Key market trends, growth factors and opportunities

6.0.2 Market size and forecast, by region

6.0.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Small Molecules

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Large Molecules

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 Pharmaceutical and Biotechnology companies

7.2.1 Key market trends, growth factors and opportunities

7.2.2 Market size and forecast, by region

7.2.3 Market share analysis by country

7.3 Academic Institutes

7.3.1 Key market trends, growth factors and opportunities

7.3.2 Market size and forecast, by region

7.3.3 Market share analysis by country

7.4 Others

7.4.1 Key market trends, growth factors and opportunities

7.4.2 Market size and forecast, by region

7.4.3 Market share analysis by country

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key trends and opportunities

8.2.2 North America Market size and forecast, by Workflow

8.2.3 North America Market size and forecast, by Therapeutic area

8.2.4 North America Market size and forecast, by Drug Type

8.2.5 North America Market size and forecast, by End User

8.2.6 North America Market size and forecast, by country

8.2.6.1 U.S.

8.2.6.1.1 Key market trends, growth factors and opportunities

8.2.6.1.2 Market size and forecast, by Workflow

8.2.6.1.3 Market size and forecast, by Therapeutic area

8.2.6.1.4 Market size and forecast, by Drug Type

8.2.6.1.5 Market size and forecast, by End User

8.2.6.2 Canada

8.2.6.2.1 Key market trends, growth factors and opportunities

8.2.6.2.2 Market size and forecast, by Workflow

8.2.6.2.3 Market size and forecast, by Therapeutic area

8.2.6.2.4 Market size and forecast, by Drug Type

8.2.6.2.5 Market size and forecast, by End User

8.2.6.3 Mexico

8.2.6.3.1 Key market trends, growth factors and opportunities

8.2.6.3.2 Market size and forecast, by Workflow

8.2.6.3.3 Market size and forecast, by Therapeutic area

8.2.6.3.4 Market size and forecast, by Drug Type

8.2.6.3.5 Market size and forecast, by End User

8.3 Europe

8.3.1 Key trends and opportunities

8.3.2 Europe Market size and forecast, by Workflow

8.3.3 Europe Market size and forecast, by Therapeutic area

8.3.4 Europe Market size and forecast, by Drug Type

8.3.5 Europe Market size and forecast, by End User

8.3.6 Europe Market size and forecast, by country

8.3.6.1 Germany

8.3.6.1.1 Key market trends, growth factors and opportunities

8.3.6.1.2 Market size and forecast, by Workflow

8.3.6.1.3 Market size and forecast, by Therapeutic area

8.3.6.1.4 Market size and forecast, by Drug Type

8.3.6.1.5 Market size and forecast, by End User

8.3.6.2 France

8.3.6.2.1 Key market trends, growth factors and opportunities

8.3.6.2.2 Market size and forecast, by Workflow

8.3.6.2.3 Market size and forecast, by Therapeutic area

8.3.6.2.4 Market size and forecast, by Drug Type

8.3.6.2.5 Market size and forecast, by End User

8.3.6.3 UK

8.3.6.3.1 Key market trends, growth factors and opportunities

8.3.6.3.2 Market size and forecast, by Workflow

8.3.6.3.3 Market size and forecast, by Therapeutic area

8.3.6.3.4 Market size and forecast, by Drug Type

8.3.6.3.5 Market size and forecast, by End User

8.3.6.4 Italy

8.3.6.4.1 Key market trends, growth factors and opportunities

8.3.6.4.2 Market size and forecast, by Workflow

8.3.6.4.3 Market size and forecast, by Therapeutic area

8.3.6.4.4 Market size and forecast, by Drug Type

8.3.6.4.5 Market size and forecast, by End User

8.3.6.5 Spain

8.3.6.5.1 Key market trends, growth factors and opportunities

8.3.6.5.2 Market size and forecast, by Workflow

8.3.6.5.3 Market size and forecast, by Therapeutic area

8.3.6.5.4 Market size and forecast, by Drug Type

8.3.6.5.5 Market size and forecast, by End User

8.3.6.6 Rest of Europe

8.3.6.6.1 Key market trends, growth factors and opportunities

8.3.6.6.2 Market size and forecast, by Workflow

8.3.6.6.3 Market size and forecast, by Therapeutic area

8.3.6.6.4 Market size and forecast, by Drug Type

8.3.6.6.5 Market size and forecast, by End User

8.4 Asia-Pacific

8.4.1 Key trends and opportunities

8.4.2 Asia-Pacific Market size and forecast, by Workflow

8.4.3 Asia-Pacific Market size and forecast, by Therapeutic area

8.4.4 Asia-Pacific Market size and forecast, by Drug Type

8.4.5 Asia-Pacific Market size and forecast, by End User

8.4.6 Asia-Pacific Market size and forecast, by country

8.4.6.1 Japan

8.4.6.1.1 Key market trends, growth factors and opportunities

8.4.6.1.2 Market size and forecast, by Workflow

8.4.6.1.3 Market size and forecast, by Therapeutic area

8.4.6.1.4 Market size and forecast, by Drug Type

8.4.6.1.5 Market size and forecast, by End User

8.4.6.2 China

8.4.6.2.1 Key market trends, growth factors and opportunities

8.4.6.2.2 Market size and forecast, by Workflow

8.4.6.2.3 Market size and forecast, by Therapeutic area

8.4.6.2.4 Market size and forecast, by Drug Type

8.4.6.2.5 Market size and forecast, by End User

8.4.6.3 Australia

8.4.6.3.1 Key market trends, growth factors and opportunities

8.4.6.3.2 Market size and forecast, by Workflow

8.4.6.3.3 Market size and forecast, by Therapeutic area

8.4.6.3.4 Market size and forecast, by Drug Type

8.4.6.3.5 Market size and forecast, by End User

8.4.6.4 India

8.4.6.4.1 Key market trends, growth factors and opportunities

8.4.6.4.2 Market size and forecast, by Workflow

8.4.6.4.3 Market size and forecast, by Therapeutic area

8.4.6.4.4 Market size and forecast, by Drug Type

8.4.6.4.5 Market size and forecast, by End User

8.4.6.5 South Korea

8.4.6.5.1 Key market trends, growth factors and opportunities

8.4.6.5.2 Market size and forecast, by Workflow

8.4.6.5.3 Market size and forecast, by Therapeutic area

8.4.6.5.4 Market size and forecast, by Drug Type

8.4.6.5.5 Market size and forecast, by End User

8.4.6.6 Rest of Asia-Pacific

8.4.6.6.1 Key market trends, growth factors and opportunities

8.4.6.6.2 Market size and forecast, by Workflow

8.4.6.6.3 Market size and forecast, by Therapeutic area

8.4.6.6.4 Market size and forecast, by Drug Type

8.4.6.6.5 Market size and forecast, by End User

8.5 LAMEA

8.5.1 Key trends and opportunities

8.5.2 LAMEA Market size and forecast, by Workflow

8.5.3 LAMEA Market size and forecast, by Therapeutic area

8.5.4 LAMEA Market size and forecast, by Drug Type

8.5.5 LAMEA Market size and forecast, by End User

8.5.6 LAMEA Market size and forecast, by country

8.5.6.1 Brazil

8.5.6.1.1 Key market trends, growth factors and opportunities

8.5.6.1.2 Market size and forecast, by Workflow

8.5.6.1.3 Market size and forecast, by Therapeutic area

8.5.6.1.4 Market size and forecast, by Drug Type

8.5.6.1.5 Market size and forecast, by End User

8.5.6.2 Saudi Arabia

8.5.6.2.1 Key market trends, growth factors and opportunities

8.5.6.2.2 Market size and forecast, by Workflow

8.5.6.2.3 Market size and forecast, by Therapeutic area

8.5.6.2.4 Market size and forecast, by Drug Type

8.5.6.2.5 Market size and forecast, by End User

8.5.6.3 South Africa

8.5.6.3.1 Key market trends, growth factors and opportunities

8.5.6.3.2 Market size and forecast, by Workflow

8.5.6.3.3 Market size and forecast, by Therapeutic area

8.5.6.3.4 Market size and forecast, by Drug Type

8.5.6.3.5 Market size and forecast, by End User

8.5.6.4 Rest of LAMEA

8.5.6.4.1 Key market trends, growth factors and opportunities

8.5.6.4.2 Market size and forecast, by Workflow

8.5.6.4.3 Market size and forecast, by Therapeutic area

8.5.6.4.4 Market size and forecast, by Drug Type

8.5.6.4.5 Market size and forecast, by End User

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Key developments

10.1 . Charles River Laboratories,

10.1.1 Company overview

10.1.2 Company snapshot

10.1.3 Operating business segments

10.1.4 Product portfolio

10.1.5 Business performance

10.1.6 Key strategic moves and developments

10.2 Curia Global Inc

10.2.1 Company overview

10.2.2 Company snapshot

10.2.3 Operating business segments

10.2.4 Product portfolio

10.2.5 Business performance

10.2.6 Key strategic moves and developments

10.3 Dr. Reddy's Laboratories

10.3.1 Company overview

10.3.2 Company snapshot

10.3.3 Operating business segments

10.3.4 Product portfolio

10.3.5 Business performance

10.3.6 Key strategic moves and developments

10.4 Dalton Pharma Service

10.4.1 Company overview

10.4.2 Company snapshot

10.4.3 Operating business segments

10.4.4 Product portfolio

10.4.5 Business performance

10.4.6 Key strategic moves and developments

10.5 Discover X Corporation

10.5.1 Company overview

10.5.2 Company snapshot

10.5.3 Operating business segments

10.5.4 Product portfolio

10.5.5 Business performance

10.5.6 Key strategic moves and developments

10.6 Laboratory Corporation of America Holdings

10.6.1 Company overview

10.6.2 Company snapshot

10.6.3 Operating business segments

10.6.4 Product portfolio

10.6.5 Business performance

10.6.6 Key strategic moves and developments

10.7 Merck & Co

10.7.1 Company overview

10.7.2 Company snapshot

10.7.3 Operating business segments

10.7.4 Product portfolio

10.7.5 Business performance

10.7.6 Key strategic moves and developments

10.8 Syngene International Ltd

10.8.1 Company overview

10.8.2 Company snapshot

10.8.3 Operating business segments

10.8.4 Product portfolio

10.8.5 Business performance

10.8.6 Key strategic moves and developments

10.9 Thermo Fisher Scientific, Inc.

10.9.1 Company overview

10.9.2 Company snapshot

10.9.3 Operating business segments

10.9.4 Product portfolio

10.9.5 Business performance

10.9.6 Key strategic moves and developments

10.10 TCG Life Science Pvt. Ltd

10.10.1 Company overview

10.10.2 Company snapshot

10.10.3 Operating business segments

10.10.4 Product portfolio

10.10.5 Business performance

10.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 2. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 8. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 10. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 11. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 13. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 14. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 15. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 16. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 17. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 18. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 19. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 20. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 21. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 22. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 23. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 24. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 25. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 26. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 27. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 28. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 29. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 30. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 32. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 33. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 34. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 35. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 37. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 38. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 39. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 40. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 41. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 42. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 43. DRUG DISCOVERY OUTSOURCING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 44. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 45. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 46. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 47. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 48. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 49. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 50. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 51. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 52. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 53. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 54. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 55. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 56. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 57. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 58. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 59. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 60. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 61. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 62. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 63. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 64. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 65. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 66. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 67. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 68. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 69. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 70. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 71. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 72. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 73. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 74. UK DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 75. UK DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 76. UK DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 77. UK DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 78. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 79. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 80. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 81. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 82. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 83. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 84. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 86. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 87. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 88. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 89. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 90. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 91. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 92. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 93. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 94. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 95. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 96. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 97. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 98. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 99. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 100. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 101. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 102. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 103. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 104. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 105. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 106. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 107. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 108. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 109. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 110. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 111. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 112. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 113. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 114. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 115. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 116. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 117. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 118. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 119. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 120. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 121. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 122. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 123. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 124. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 125. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 126. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 127. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 128. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 129. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 130. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 131. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 132. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 133. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 134. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 135. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 136. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)

TABLE 137. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 138. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 139. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 140.. CHARLES RIVER LABORATORIES,: COMPANY SNAPSHOT

TABLE 141.. CHARLES RIVER LABORATORIES,: OPERATING SEGMENTS

TABLE 142.. CHARLES RIVER LABORATORIES,: PRODUCT PORTFOLIO

TABLE 143.. CHARLES RIVER LABORATORIES,: NET SALES

TABLE 144.. CHARLES RIVER LABORATORIES,: KEY STRATERGIES

TABLE 145.CURIA GLOBAL INC: COMPANY SNAPSHOT

TABLE 146.CURIA GLOBAL INC: OPERATING SEGMENTS

TABLE 147.CURIA GLOBAL INC: PRODUCT PORTFOLIO

TABLE 148.CURIA GLOBAL INC: NET SALES

TABLE 149.CURIA GLOBAL INC: KEY STRATERGIES

TABLE 150.DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT

TABLE 151.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS

TABLE 152.DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO

TABLE 153.DR. REDDY'S LABORATORIES: NET SALES

TABLE 154.DR. REDDY'S LABORATORIES: KEY STRATERGIES

TABLE 155.DALTON PHARMA SERVICE: COMPANY SNAPSHOT

TABLE 156.DALTON PHARMA SERVICE: OPERATING SEGMENTS

TABLE 157.DALTON PHARMA SERVICE: PRODUCT PORTFOLIO

TABLE 158.DALTON PHARMA SERVICE: NET SALES

TABLE 159.DALTON PHARMA SERVICE: KEY STRATERGIES

TABLE 160.DISCOVER X CORPORATION: COMPANY SNAPSHOT

TABLE 161.DISCOVER X CORPORATION: OPERATING SEGMENTS

TABLE 162.DISCOVER X CORPORATION: PRODUCT PORTFOLIO

TABLE 163.DISCOVER X CORPORATION: NET SALES

TABLE 164.DISCOVER X CORPORATION: KEY STRATERGIES

TABLE 165.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT

TABLE 166.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS

TABLE 167.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO

TABLE 168.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES

TABLE 169.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES

TABLE 170.MERCK & CO: COMPANY SNAPSHOT

TABLE 171.MERCK & CO: OPERATING SEGMENTS

TABLE 172.MERCK & CO: PRODUCT PORTFOLIO

TABLE 173.MERCK & CO: NET SALES

TABLE 174.MERCK & CO: KEY STRATERGIES

TABLE 175.SYNGENE INTERNATIONAL LTD: COMPANY SNAPSHOT

TABLE 176.SYNGENE INTERNATIONAL LTD: OPERATING SEGMENTS

TABLE 177.SYNGENE INTERNATIONAL LTD: PRODUCT PORTFOLIO

TABLE 178.SYNGENE INTERNATIONAL LTD: NET SALES

TABLE 179.SYNGENE INTERNATIONAL LTD: KEY STRATERGIES

TABLE 180.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT

TABLE 181.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS

TABLE 182.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO

TABLE 183.THERMO FISHER SCIENTIFIC, INC.: NET SALES

TABLE 184.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES

TABLE 185.TCG LIFE SCIENCE PVT. LTD: COMPANY SNAPSHOT

TABLE 186.TCG LIFE SCIENCE PVT. LTD: OPERATING SEGMENTS

TABLE 187.TCG LIFE SCIENCE PVT. LTD: PRODUCT PORTFOLIO

TABLE 188.TCG LIFE SCIENCE PVT. LTD: NET SALES

TABLE 189.TCG LIFE SCIENCE PVT. LTD: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION

FIGURE 2.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031

FIGURE 3.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.DRUG DISCOVERY OUTSOURCING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.DRUG DISCOVERY OUTSOURCING MARKET,BY WORKFLOW,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TARGET IDENTIFICATION AND SCREENING DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGET VALIDATION AND FUNCTIONAL INFORMATICS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DEVELOPMENT DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 18.DRUG DISCOVERY OUTSOURCING MARKET,BY THERAPEUTIC AREA,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF RESPIRATORY SYSTEM DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF IMMUNOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 28.DRUG DISCOVERY OUTSOURCING MARKET,BY DRUG TYPE,2021(%)

FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LARGE MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 31.DRUG DISCOVERY OUTSOURCING MARKET,BY END USER,2021(%)

FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 33.COMPARATIVE SHARE ANALYSIS OF ACADEMIC INSTITUTES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 34.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)

FIGURE 35.DRUG DISCOVERY OUTSOURCING MARKET BY REGION,2021

FIGURE 36.U.S. DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 37.CANADA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 38.MEXICO DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 39.GERMANY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 40.FRANCE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 41.UK DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 42.ITALY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 43.SPAIN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 44.REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 45.JAPAN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 46.CHINA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 47.AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 48.INDIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 49.SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 50.REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 51.BRAZIL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 52.SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 53.SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 54.REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)

FIGURE 55. TOP WINNING STRATEGIES, BY YEAR

FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 59.COMPETITIVE DASHBOARD

FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 61.. CHARLES RIVER LABORATORIES,.: NET SALES ($MILLION)

FIGURE 62.CURIA GLOBAL INC.: NET SALES ($MILLION)

FIGURE 63.DR. REDDY'S LABORATORIES.: NET SALES ($MILLION)

FIGURE 64.DALTON PHARMA SERVICE.: NET SALES ($MILLION)

FIGURE 65.DISCOVER X CORPORATION.: NET SALES ($MILLION)

FIGURE 66.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ($MILLION)

FIGURE 67.MERCK & CO.: NET SALES ($MILLION)

FIGURE 68.SYNGENE INTERNATIONAL LTD.: NET SALES ($MILLION)

FIGURE 69.THERMO FISHER SCIENTIFIC, INC..: NET SALES ($MILLION)

FIGURE 70.TCG LIFE SCIENCE PVT. LTD.: NET SALES ($MILLION